October 25th 2021, 5:00pm
The first-of-its-kind port delivery system with ranibizumab serves as the first wet age-related macular degeneration (AMD) treatment in 15 years to provide an alternative to frequent eye injections.
October 23rd 2021, 3:00pm
Approximately half of patients with proliferative diabetic retinopathy exhibited long lapses in care when prescribed ranibizumab across a 5-year follow-up.
October 21st 2021, 5:30pm
Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.
October 14th 2021, 7:00pm
October 11th 2021, 5:30pm
An evaluation of price transparency tools for ophthalmologic procedures found significant usability, availability, and variability issues, which may disproportionately impact vulnerable populations.
October 7th 2021, 1:00pm
October 5th 2021, 6:30pm
Male patients with young-onset type 2 diabetes were found to be at 72% greater risk of retinopathy compared with those who received a diagnosis at 50 years or older.
September 30th 2021, 8:00pm
September 28th 2021, 5:30pm
Risk of diabetic retinopathy (DR) was found to be decreased in young patients with type 1 diabetes (T1D) who were treated with insulin pumps, with findings also indicating a 2.1-fold greater risk of DR in Black participants compared with White individuals.
September 24th 2021, 3:00pm
Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, addresses ongoing and future innovations in eye lens technology and instruments for cataract surgery.
